A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.

Although a large number of drugs have been used to treat chronic hepatitis C (CHC), there still remains a great challenge to treat maintenance hemodialysis (MHD) patients with chronic hepatitis C. To clarify the immunnoloregulation of double filtration plasmapheresis (DFPP) in MHD patients with CHC,...

Full description

Bibliographic Details
Main Authors: Hongdi Cao, Ping Wen, Hong Ye, Zhiping Sun, Xia Shen, Xiaochun Wu, Chunsun Dai, Junwei Yang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3864956?pdf=render
id doaj-fca0da49d07044e282026166a5057a24
record_format Article
spelling doaj-fca0da49d07044e282026166a5057a242020-11-25T01:12:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8252410.1371/journal.pone.0082524A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.Hongdi CaoPing WenHong YeZhiping SunXia ShenXiaochun WuChunsun DaiJunwei YangAlthough a large number of drugs have been used to treat chronic hepatitis C (CHC), there still remains a great challenge to treat maintenance hemodialysis (MHD) patients with chronic hepatitis C. To clarify the immunnoloregulation of double filtration plasmapheresis (DFPP) in MHD patients with CHC, DFPP was performed in 20 MHD patients with CHC (HCV-antibody positive, serum HCV RNA >500 IU/ml more than 6 months and HCV genotype 1b). The clinical data was collected and peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry at the time of hour 0, hour 3, day 3, day 7 and day 28 after the DFPP, respectively. Serum HCV particles could be removed partially by the DFPP. The titer of serum HCV RNA could remain in a lower level even 28 days after the treatment. Compared to MHD patients without HCV infection, the frequencies of innate immune cells were similar in MHD patients with CHC, while Th1/Th2 was elevated and the frequencies of regulatory T (Treg) cells were higher in those MHD patients with CHC. The frequencies of monocytes and natural killer (NK) cells remained after the DFPP in MHD patients with CHC. There were no significant changes of Th1, Th2 and Th1/Th2 in PBMC after DFPP. DFPP could reduce the frequencies of Th17 cells and Treg cells in PBMC from 7 days after DFPP in MHD patients with CHC. DFPP could partially remove the serum HCV particles mechanically. The titer of HCV RNA could remain in a lower level at least for 28 days probably due to the redistribution of the immunocytes in circulation.http://europepmc.org/articles/PMC3864956?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Hongdi Cao
Ping Wen
Hong Ye
Zhiping Sun
Xia Shen
Xiaochun Wu
Chunsun Dai
Junwei Yang
spellingShingle Hongdi Cao
Ping Wen
Hong Ye
Zhiping Sun
Xia Shen
Xiaochun Wu
Chunsun Dai
Junwei Yang
A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
PLoS ONE
author_facet Hongdi Cao
Ping Wen
Hong Ye
Zhiping Sun
Xia Shen
Xiaochun Wu
Chunsun Dai
Junwei Yang
author_sort Hongdi Cao
title A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
title_short A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
title_full A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
title_fullStr A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
title_full_unstemmed A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C.
title_sort study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis c.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Although a large number of drugs have been used to treat chronic hepatitis C (CHC), there still remains a great challenge to treat maintenance hemodialysis (MHD) patients with chronic hepatitis C. To clarify the immunnoloregulation of double filtration plasmapheresis (DFPP) in MHD patients with CHC, DFPP was performed in 20 MHD patients with CHC (HCV-antibody positive, serum HCV RNA >500 IU/ml more than 6 months and HCV genotype 1b). The clinical data was collected and peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry at the time of hour 0, hour 3, day 3, day 7 and day 28 after the DFPP, respectively. Serum HCV particles could be removed partially by the DFPP. The titer of serum HCV RNA could remain in a lower level even 28 days after the treatment. Compared to MHD patients without HCV infection, the frequencies of innate immune cells were similar in MHD patients with CHC, while Th1/Th2 was elevated and the frequencies of regulatory T (Treg) cells were higher in those MHD patients with CHC. The frequencies of monocytes and natural killer (NK) cells remained after the DFPP in MHD patients with CHC. There were no significant changes of Th1, Th2 and Th1/Th2 in PBMC after DFPP. DFPP could reduce the frequencies of Th17 cells and Treg cells in PBMC from 7 days after DFPP in MHD patients with CHC. DFPP could partially remove the serum HCV particles mechanically. The titer of HCV RNA could remain in a lower level at least for 28 days probably due to the redistribution of the immunocytes in circulation.
url http://europepmc.org/articles/PMC3864956?pdf=render
work_keys_str_mv AT hongdicao astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT pingwen astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT hongye astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT zhipingsun astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT xiashen astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT xiaochunwu astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT chunsundai astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT junweiyang astudyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT hongdicao studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT pingwen studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT hongye studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT zhipingsun studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT xiashen studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT xiaochunwu studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT chunsundai studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
AT junweiyang studyoftheimmunoloregulationofdoublefiltrationplasmapheresisinmaintenancehemodialysispatientswithchronichepatitisc
_version_ 1725166731047993344